# ELI LILLY & Co: overview

LLY · NYSE · CIK 59478 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lly.md) · [Financials](/companies/lly/financials.md) · [Filings](/companies/lly/filings.md) · [Insiders](/companies/lly/insiders.md)

Latest reported revenue: [$24.40bn](/filings/0000059478-26-000108.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:Revenues, accession 0000059478-26-000108).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [13.5 d](/filings/0000059478-26-000013.md) | [12.7](/filings/0000059478-26-000045.md) | [15.6](/filings/0000059478-26-000081.md) | [17.6](/filings/0000059478-26-000108.md) | [19.3 d](/filings/0000059478-26-000013.md) | [19.8](/filings/0000059478-26-000045.md) | [23.0](/filings/0000059478-26-000081.md) | [24.4](/filings/0000059478-26-000108.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [32.6% d](/filings/0000059478-26-000013.md) | [21.7%](/filings/0000059478-26-000045.md) | [36.4%](/filings/0000059478-26-000081.md) | [31.7%](/filings/0000059478-26-000108.md) | [34.4% d](/filings/0000059478-26-000013.md) | [37.4%](/filings/0000059478-26-000045.md) | [30.9%](/filings/0000059478-26-000081.md) | [26.4%](/filings/0000059478-26-000108.md) |
| Diluted EPS | $ per share | not reported | [3.06](/filings/0000059478-26-000045.md) | [6.29](/filings/0000059478-26-000081.md) | [6.21](/filings/0000059478-26-000108.md) | not reported | [8.26](/filings/0000059478-26-000045.md) | [7.94](/filings/0000059478-26-000081.md) | [7.22](/filings/0000059478-26-000108.md) |
| Free cash flow | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [28.3](/filings/0000059478-24-000065.md) | [28.5](/filings/0000059478-25-000067.md) | [34.1](/filings/0000059478-26-000013.md) | [45.0](/filings/0000059478-26-000013.md) | [65.2](/filings/0000059478-26-000013.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [19.7%](/filings/0000059478-24-000065.md) | [21.9%](/filings/0000059478-25-000067.md) | [15.4%](/filings/0000059478-26-000013.md) | [23.5%](/filings/0000059478-26-000013.md) | [31.7%](/filings/0000059478-26-000013.md) |
| Diluted EPS | $ per share | [6.12](/filings/0000059478-24-000065.md) | [6.90](/filings/0000059478-25-000067.md) | [5.80](/filings/0000059478-26-000013.md) | [11.71](/filings/0000059478-26-000013.md) | [22.95](/filings/0000059478-26-000013.md) |
| Free cash flow | $bn | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lly/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [LILLY ENDOWMENT INC](/funds/316011.md) | 2026-06-30 | $108.40bn | 90,376,978 |  | Reduced −1,520,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $81.01bn | 67,540,400 |  | Added +1,159,558 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $64.20bn | 53,528,868 |  | Added +167,094 |
| [PNC Financial Services Group, Inc.](/funds/713676.md) | 2026-06-30 | $61.56bn | 51,322,720 |  | Reduced −6,188 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $43.44bn | 36,215,754 |  | Added +605,752 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $34.14bn | 28,462,475 |  | Added +2,121,444 |
| [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $25.04bn | 20,873,140 |  | Reduced −3,759,507 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $25.02bn | 20,859,217 |  | Reduced −117,810 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $24.28bn | 20,310,858 |  | Added +118,994 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $19.46bn | 16,226,398 |  | Added +788,940 |

## Recent filings

[All 2,828 filings](/companies/lly/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 11:35 ET | [10-Q](/filings/0000059478-26-000108.md) | Quarterly report, period 2026-09-30 | 0000059478-26-000108 |
| 2026-10-29 | 07:03 ET | [8-K](/filings/0000059478-26-000104.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000059478-26-000104 |
| 2026-10-16 | 16:19 ET | [SCHEDULE 13D](/filings/0000059478-26-000095.md) | Ownership report, active investor | 0000059478-26-000095 |
| 2026-08-05 | 14:40 ET | [10-Q](/filings/0000059478-26-000081.md) | Quarterly report, period 2026-06-30 | 0000059478-26-000081 |
| 2026-08-05 | 07:05 ET | [8-K](/filings/0000059478-26-000077.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000059478-26-000077 |
| 2026-07-30 | 16:39 ET | [SCHEDULE 13D](/filings/0000059478-26-000072.md) | Ownership report, active investor | 0000059478-26-000072 |
| 2026-05-20 | 16:30 ET | [8-K](/filings/0001193125-26-232707.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-232707 |
| 2026-05-07 | 16:41 ET | [8-K](/filings/0000059478-26-000048.md) | 5.07 Shareholder vote results | 0000059478-26-000048 |
| 2026-04-30 | 11:25 ET | [10-Q](/filings/0000059478-26-000045.md) | Quarterly report, period 2026-03-31 | 0000059478-26-000045 |
| 2026-04-30 | 07:03 ET | [8-K](/filings/0000059478-26-000043.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000059478-26-000043 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000059478-26-000013.md), filed Feb 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/b0a7dde5-b403-4a88-a884-3475ee394510)

## About the filer

- CIK: 59478
- Tickers: LLY
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: IN
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 14:56 ET. No prices; not investment advice.